- Report
- August 2025
- 192 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 182 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 182 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- April 2025
- 200 Pages
Global
From €3947EUR$4,490USD£3,414GBP
- Report
- September 2025
- 250 Pages
Global
From €3947EUR$4,490USD£3,414GBP
- Report
- April 2025
- 200 Pages
Global
From €3947EUR$4,490USD£3,414GBP
- Report
- September 2025
- 250 Pages
Global
From €3947EUR$4,490USD£3,414GBP
- Report
- September 2025
- 287 Pages
Global
From €5142EUR$5,850USD£4,448GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1099EUR$1,250USD£950GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1099EUR$1,250USD£950GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2451EUR$2,789USD£2,120GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2451EUR$2,789USD£2,120GBP
- Report
- June 2025
United States
From €2505EUR$2,850USD£2,167GBP
- Report
- June 2025
Latin America
From €8350EUR$9,500USD£7,223GBP
- Report
- June 2025
Europe
From €12745EUR$14,500USD£11,024GBP
- Report
- May 2024
- 137 Pages
Global
From €5712EUR$6,499USD£4,941GBP
- Report
- May 2024
- 133 Pages
Global
From €5712EUR$6,499USD£4,941GBP
- Report
- May 2024
- 138 Pages
Global
From €5712EUR$6,499USD£4,941GBP
- Report
- April 2023
- 115 Pages
Global
From €4175EUR$4,750USD£3,611GBP
- Report
- March 2024
- 200 Pages
Global
From €3648EUR$4,150USD£3,155GBP

Estradiol is a hormone used in the treatment of prostate cancer. It is a form of estrogen, and is used to reduce the levels of testosterone in the body, which can help slow the growth of prostate cancer cells. Estradiol is typically administered as an injection, and is often used in combination with other drugs to treat prostate cancer. It is also used to reduce the risk of prostate cancer recurrence after surgery. Side effects of estradiol can include hot flashes, breast tenderness, and increased risk of blood clots.
The estradiol market is a growing segment of the prostate cancer drug market. It is used in combination with other drugs to treat prostate cancer, and is increasingly being used to reduce the risk of recurrence after surgery. The market is expected to continue to grow as more patients are diagnosed with prostate cancer and the need for effective treatments increases.
Companies in the estradiol market include Pfizer, Novartis, and AstraZeneca. Show Less Read more